Show simple item record

dc.contributor.authorKatende-Kyenda, N.L.
dc.contributor.authorLubbe, M.S.
dc.contributor.authorSerfontein, J.H.P.
dc.contributor.authorTruter, I.
dc.date.accessioned2010-04-20T07:24:08Z
dc.date.available2010-04-20T07:24:08Z
dc.date.issued2008
dc.identifier.citationKatende-Kyenda, N.L. et al. 2008. Prevalence of drug-drug interactions of antiretroviral agents in the private health care sector in South Africa. SAMJ: South African medical journal, 98(2):109-113. [http://www.samj.org.za/index.php/samj/article/view/265]en
dc.identifier.issn0256-9574
dc.identifier.urihttp://hdl.handle.net/10394/2917
dc.identifier.urihttp://www.samj.org.za/index.php/samj/article/viewFile/265/714
dc.description.abstractObjectives. Human immunodefiency virus (HIV) infection can be effectively treated with highly active antiretroviral therapy (HAART), requiring concomitant administration of three to four different agents, often with a high potential for drug-drug interactions (DDIs). This study aimed to determine the prevalence of possible DDIs between antiretrovirals (ARVs) themselves and other drugs. Design. Retrospective drug-utilisation study using data from from a national medicine claims database for the period 1 January to 31 December 2004. Setting. A section of the private healthcare sector in South Africa. Subjects. All ARV prescriptions (N=43482) claimed during 2004. The possible DDIs found were classified according to a clinical significant rating as described by Tatro7 (2005) in his book, “Drug Interactions – Facts and comparisons.” Results. A total of 5305882 medicine items were prescribed, of these, 1.92% (N=101 938) accounted for ARVs. Of the total number of 2595254 prescriptions, 1.68% (N=43 482), were ARVs. A total number of 18035 DDIs (81 different types) were identified, of these, 83.89%, (n=15130) were DDIs between ARVs and other drugs, while 16.11% (n=2905) were DDIs between ARVs themselves. Possible DDIs with a clinical significance level of 1 (major, n=17) and 2 (moderate, n=1436) represented 8.06% (n=1 453) of the total number of identified interactions. Conclusions. Since concomitant use of ARVs and other drugs used to treat HIV complications is increasing, there is a great need of understanding and anticipating these DDIs, overcoming them by dose adjustments and patient education by pharmacists, so that they are not life threatening to HIV/AIDS patients
dc.language.isoenen
dc.publisherHealth & Medical Publishing Groupen
dc.subjectDrug-drug interactions
dc.subjectAntiretroviral agents
dc.titlePrevalence of drug-drug interactions of antiretroviral agents in the private health care sector in South Africaen
dc.typeArticleen
dc.contributor.researchID10069712 - Lubbe, Martha Susanna
dc.contributor.researchID10054553 - Serfontein, Jan Hendrik Philippus


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record